#United States #New York #SueWallSt #Fractyl Health #GUTS

Fractyl Health Shareholders Beware: Class Action Lawsuit

A recent notification from SueWallSt has drawn attention to a class action lawsuit targeting Fractyl Health, Inc. (NASDAQ: GUTS). The lawsuit centers around allegations that Fractyl misrepresented the clinical efficacy of its weight loss device, the Revita DMR System. Investors who purchased shares between January 13, 2025, and January 29, 2026, are encouraged to act before the deadline to join the suit by October 20, 2026.

Background of the Allegations

Fractyl Health's Revita system was promoted as a revolutionary one-time endoscopic treatment that would help patients maintain weight loss post-discontinuation of GLP-1 drugs, which reportedly presents a $175 billion market opportunity. The company touted significant weight loss among users during interim analyses, describing the results as bold and unprecedented. However, legal claims are challenging these assertions, indicating that Fractyl may have failed to adequately disclose operational failures at a major REMAIN-1 study site, which affected the integrity and reliability of their reported data.

The Financial Impact on Investors

During the span of the class period, GUTS experienced a sharp decline of approximately 74.86%, with share prices plummeting from $1.83 to $0.46 following the report of disappointing data from the six-month REMAIN-1 study. Specifically, the data revealed that patients in the Revita group regained 4.5% of their weight compared to 7.5% in the control group—far below optimistic forecasts and assertions made by Fractyl Health.

Key Points of the Lawsuit

- Investor Claims: The lawsuit points to misleading statements regarding the clinical efficacy of Revita and the operational status of the involved study sites. Investors allege that Fractyl did not fully disclose the conditions that led to skewed study results, which would ultimately jeopardize the expected outcomes.
- Financial Disclosures: The complaint also brings attention to potential lack of clarity in risk disclosures mandated under Regulation S-K, raising questions about the viability and safety of investments made during the class period. Fractyl's capital raises, totaling approximately $20.7 million in August 2025 and $56 million in September 2025, occurred while key operational issues were reportedly hidden from investors.

Know Your Rights as a Shareholder

Joseph E. Levi, Esq., a representative from SueWallSt, stated, “This case poses crucial inquiries regarding the duty of clinical data disclosure in the medical device industry, especially concerning how site-level conditions may impact efficacy results.” Investors who purchased GUTS shares and suffered losses are encouraged to seek evaluation for potential recovery of their investments through this class action.

Steps for Interested Investors

If you are a GUTS investor affected by these issues, follow these guidelines:
1. Gather Your Documentation: Collect your brokerage statements evidencing your purchase dates, number of shares, and amounts paid.
2. Register Your Claims: Submit your information for a no-cost evaluation by SueWallSt to see if you qualify to benefit from any potential recovery route.
3. Stay Informed: Keep track of updates regarding the lawsuit and its developments as the deadline approaches in October.

For more information or assistance, reach out to Joseph E. Levi at [email protected] or by calling (888) SueWallSt. Participating in the class action does not typically require any upfront costs, in line with the standard contingency arrangement in cases of this nature.

Conclusion

With significant implications for shareholders, especially in a fluctuating stock like GUTS, taking timely action is crucial. Assess your eligibility and stay proactive regarding potential claims under the current class action lawsuit to safeguard your financial interests.

• ---